ASX Announcements

2019

Date Announcement
03/04/2019 Medical University Vienna presents positive new data on one of Imugene’s lead PD-1 mimotope cancer vaccines at the American Association for Cancer Research 2019 Annual Meeting
02/04/2019 New Data on Imugene’s Lead PD-1 KEY-Vaxx and HER-2 B-Vaxx Cancer Vaccines presented at the American Association for Cancer Research 2019 Annual Meeting
02/04/2019 Positive New Data on Imugene’s HER-Vaxx Cancer Vaccine Phase Ib trial presented at the American Association for Cancer Research 2019 Annual Meeting
20/03/2019 Imugene’s Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx Immunotherapy Clinical Development Plan
14/03/2019 Imugene Announces First Patient Dosed in the Open-Label Phase 2 Study with HER-Vaxx Cancer Vaccine for Advanced Gastric Cancer
04/03/2019 Imugene Announces Presentations on Lead PD-1 and HER-2 Cancer Vaccines at the American Association for Cancer Research 2019 Annual Meeting
28/02/2019 Half Yearly Report and Accounts
28/02/2019 Pause in Trading
28/02/2019 Imugene Announces Presentation on HER-Vaxx Cancer Vaccine at the American Association for Cancer Research 2019 Annual Meeting
26/02/2019 Prestigious Clinical Cancer Research Journal Publishes B-Vaxx Phase 1 Data
30/01/2019 Appendix 4C - Quarterly and Business Update
10/01/2019 Investor Presentation
07/01/2019 Imugene appoints distinguished scientist, Dr Michael Caligiuri of City of Hope to Scientific Advisory Board

 

2018

Date Announcement
20/12/2018 Change of Director's Interest Notice - PH
17/12/2018 Imugene Meets Endpoints in Phase 1b Gastric Cancer Immuno-oncology Trial
21/11/2018 IMU Meets Endpoints in Phase 1b Gastric Cancer Trial
21/11/2018 Change of Director's Interest Notice - LC
21/11/2018 Appendix 3B and 708A Notice
21/11/2018 Change of Director's Interest Notice - PH
13/11/2018 Results of Meeting
13/11/2018 AGM Presentation
13/11/2018 Imugene Advances to Phase 2 in Gastric Cancer Immuno-oncology Trial
09/11/2018 Imugene Received $1.85 million R&D Tax Incentive
30/10/2018 Appendix 4C - quarterly
22/10/2018 Change of Director's Interest Notice - AH
22/10/2018 Appendix 3B (Exercise of Options) and 708A Notice
09/10/2018 Notice of Annual General Meeting
08/10/2018 Change in Executive Remuneration
04/10/2018 European Society for Medical Oncology President joins Imugene Scientific Advisory Board
01/10/2018 Imugene appoints leading cancer researcher to Scientific Advisory Board
28/09/2018 Appendix 4G
21/09/2018 Imugene commences cGMP manufacture of PD-1 cancer vaccine
18/09/2018 Imugene appoints gastrointestinal cancer expert to Scientific Advisory Board
11/09/2018 Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment
31/08/2018 Appendix 4E and Audited Financial Report
23/08/2018 Imugene appoints Dr Mark Marino Chief Medical Officer
27/07/2018 2018 Bioshares Presentation
23/07/2018 PD-1 cancer vaccine development update
07/06/2018 Capital Raising Presentation
07/06/2018 Prospectus
07/06/2018 Imugene to Raise A$20.1 million
07/06/2018 Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio
05/06/2018 Trading Halt
28/03/2018 Leslie Chong Appointed as Managing Director
18/02/2018 Imugene arginine modulator demonstrates activity in melanoma cancer model
11/02/2018 Novel Anti-PD-1 Mimotope Vaccine Ready for Development
09/02/2018 Imugene hosts investigator meeting for gastric cancer clinical trial
07/02/2018 Cancer vaccine shows early promise in gastric cancer clinical trial
29/01/2018 Business Update – December Quarter Appendix 4C

 

2017

Date Announcement
04/12/2017 International Cancer Specialist Joins Imugene’s SAB
23/11/2017 IMUGENE RAISES $8.7 MILLION
23/11/2017 IMU - Prospectus
23/11/2017 IMU Capital Raising Presentation
23/11/2017 Entitlement Offer - notice to option holders
23/11/2017 Entitlement Offer - notice to ineligible shareholders
23/11/2017 Entitlement Offer – notice to eligible shareholders
24/10/2017 Imugene Limited to Present at Australia Biotech Invest 2017
16/10/2017 Expert briefing and Q&A 
11/10/2017 Imugene Receives $1.1 million in Research and Development Tax Refund
06/10/2017 Imugene Investor Presentation
31/08/2017 Imugene commences first patient dosing of HER-Vaxx
21/07/2017 Canadian patent granted for HER-Vaxx
17/07/2017 Investor Presentation July 2017
26/06/2017 Change of Address
30/03/2017 $1.35 million Options Underwritten
27/02/2017 Intellectual Property Strengthened Around Lead Clinical Drug HER-Vaxx
13/02/2017 Prestigious BMC Cancer journal publishes encouraging HER-Vaxx research
09/01/2017 Presentation by Leslie Chong at 9th Annual Biotech Showcase, San Francisco 9 Jan 17
 
Animoca Brands
Arbortech
Blooms the Chemist
Crestone
Federation Alternative Investments
Genex Power
Haoma Mining
Invigor
Pharmaxis
Planet Innovation Holdings
PrimaryMarkets
VGW Holdings
Waratah Hotel Group
Sample Trading Hub
Imugene
Capital Raises
Secondary Trading
Funds Example

VIEW OUR VIDEOS

Become a Follower